BACKGROUND
Myelofibrosis (MF) is a myeloid bone marrow malignancy with a progressive clinical course marked by disease-related symptoms, splenomegaly, cytopenias, thrombosis/hemorrhage, and a risk for blast phase transformation. Treatment recommendations are based on the burden of symptoms, prognosis of the disease, an...
B. Stein, Maya Abdallah, Gregory A. Abel et al.· Blood Advances· 0 citations
Current off-the-shelf LLMs cannot reliably perform ROBINS-I risk of bias assessments, as Claude was internally consistent but poorly aligned with human reviewers and GPT had lower reliability and mixed accuracy.
S. Saadi, Farah Fleti, Omar H. Rajjoub et al.· BMJ digital health & AI· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.